

CLINICAL TRIALS AND OBSERVATIONS

Early progression as a predictor of survival in marginal zone lymphomas: an analysis from the FIL-NF10 study

Stefano Luminari,^{1,2} Michele Merli,³ Sara Rattotti,⁴ Vittoria Tarantino,^{5,6} Luigi Marcheselli,⁷ Federica Cavallo,^{8,9} Marzia Varettoni,⁴ Benedetta Bianchi,³ Francesco Merli,¹ Alessandra Tedeschi,¹⁰ Giuseppina Cabras,¹¹ Francesca Re,¹² Carlo Visco,¹³ Marcia Torresan Delamain,¹⁴ Emanuele Cencini,¹⁵ Michele Spina,¹⁶ Simone Ferrero,^{8,9} Angela Ferrari,¹ Marina Deodato,¹⁰ Donato Mannina,¹⁷ Ombretta Annibaldi,¹⁸ Angela Rago,¹⁹ Lorella Orsucci,²⁰ Irene Defrancesco,⁴ Marco Frigeni,²¹ Marina Cesaretti,⁷ and Luca Arcaini^{4,21}

¹Division of Hematology, Azienda Unità Sanitaria Locale Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Reggio Emilia, Reggio Emilia, Italy; ²Surgical, Medical and Dental Department of Morphological Sciences related to the Transplant, Oncology and Regenerative Medicine Department, University of Modena and Reggio Emilia, Modena, Italy; ³Division of Hematology, University Hospital Ospedale di Circolo e Fondazione Macchi–Azienda Socio-Sanitaria Territoriale Sette Laghi, University of Insubria, Varese, Italy; ⁴Division of Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; ⁵PhD Program in Clinical and Experimental Medicine, University of Modena and Reggio Emilia, Modena, Italy; ⁶Lymphoma Unit, Department of Onco-hematology, IRCCS San Raffaele Scientific Institute, Milan, Italy; ⁷Fondazione Italiana Linfomi, Modena, Italy; ⁸Hematology Division, Department of Molecular Biotechnologies and Health Sciences, University of Turin, Turin, Italy; ⁹Division of Hematology 1, Azienda Ospedaliera Universitaria (AOU) Città della Salute e della Scienza di Torino, Turin, Italy; ¹⁰Department of Hematology, Niguarda Cancer Center, Niguarda Hospital, Milan, Italy; ¹¹Division of Hematology, Ospedale Oncologico Armando Businco, Cagliari, Italy; ¹²Division of Hematology, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy; ¹³Section of Hematology, Department of Medicine, University of Verona, Verona, Italy; ¹⁴Center of Hematology and Hemotherapy, Department of Internal Medicine, Faculty of Medicine, State University of Campinas, Campinas, Brazil; ¹⁵Division of Hematology, Department of Oncology, Azienda Ospedaliera Universitaria Senese and University of Siena, Siena, Italy; ¹⁶Division of Medical Oncology A, National Cancer Institute, Aviano, Italy; ¹⁷Department of Hematology, Azienda Ospedaliera Papardo, Messina, Italy; ¹⁸Unit of Hematology, Stem Cell Transplantation, Transfusion Medicine and Cellular Therapy, University Campus Bio-Medico, Rome, Italy; ¹⁹Department of Cellular Biotechnology and Hematology, University La Sapienza, Rome, Italy; ²⁰Division of Hematology 2, AOU Città della Salute e della Scienza di Torino, Turin, Italy; and ²¹Department of Molecular Medicine, University of Pavia, Pavia, Italy

KEY POINTS

- Patients with MZL who experience POD24 from initial systemic therapy have a significantly increased risk of death.
- Association of POD24 with survival is confirmed for the main MZL subtypes.

Marginal zone lymphomas (MZLs) are indolent nonfollicular B-cell lymphomas (INFLs) and have heterogeneous clinical behavior. Recently, time to progression of disease at 24 months (POD24) was identified to stratify overall survival (OS) in follicular non-Hodgkin lymphoma and in INFL. Here, we examined the ability of POD24 to predict subsequent OS in a large, international cohort of MZL as part of the NF10 prospective international registry headed by Fondazione Italiana Linfomi (FIL). POD24 was only calculated for MZL patients requiring immediate therapy and was defined as experiencing lymphoma progression within 24 months from diagnosis. Among the 1325 patients enrolled in the NF10 study, we identified 321 patients with MZL for whom immediate therapy was planned right after lymphoma diagnosis. Overall, POD24 was confirmed in 59 patients (18%). Three-year OS for patients with POD24 was 53% with a hazard ratio of 19.5 (95% confidence interval, 8.4-45) compared with patients without POD24 (3-year OS, 95%). Association of POD24

with OS was confirmed for the subgroup of splenic and extranodal MZLs. Assessment of POD24 stratifies subsequent outcome in MZL and identifies a high-risk population. This trial was registered at www.clinicaltrials.gov as #NCT02904577. (*Blood*. 2019;134(10):798-801)

Introduction

Marginal zone lymphomas (MZLs) originate from mature B lymphocytes, and include splenic MZL (SMZL), nodal MZL (NMZL), and extranodal MZL (ENMZL) subtypes.¹ Despite their indolent course, a high heterogeneity of clinical behavior exists that warrants accurate tools to estimate the risk of relapse, progression, or death in the individual patient. A prognostic index to foresee the outcome of all patients with MZL is missing, but subtype-specific indexes have been proposed and validated for ENMZL² and for SMZL.^{3,4} Recently, the analysis of progression-free survival (PFS) has been used to identify surrogate end points in B-cell non-Hodgkin lymphomas, with

progression of disease at 24 months (POD24) identified to stratify overall survival (OS) in follicular non-Hodgkin lymphoma.⁵ Association of POD24 with OS has been confirmed in follicular lymphoma (FL), mantle cell lymphomas, diffuse large B-cell, and in peripheral T-cell lymphoma and, recently, also in indolent nonfollicular B-cell lymphomas (INFLs).⁶⁻⁹

The NF10 Project was started in 2010 as a prospective observational study specifically conceived to investigate the outcome of INFL. We examined the ability of POD24 to predict subsequent OS in the large MZL cohort of patients enrolled in the NF10 study.

Table 1. Characteristics of the 321 MZL patients who received immediate systemic therapy (study population) and comparison with MZL patients enrolled in the NF10 who did not receive immediate therapy

| Factor | Missing | Untreated, n (%) | Treated, n (%) | P |
|-------------------------------------|---------|------------------|----------------|-------|
| Total | | 286 | 321 | |
| MZL* | | | | |
| ENMZL | — | 96 (34) | 146 (46) | <.001 |
| SMZL | — | 122 (43) | 84 (26) | |
| NMZL | — | 30 (10) | 32 (10) | |
| Diss-MZL | — | 38 (13) | 59 (18) | |
| Age >60 y | — | 203 (71) | 202 (62) | .039 |
| ECOG PS >1 | 3 | 8 (3) | 21 (7) | .036 |
| Symptoms, B | 3 | 19 (7) | 66 (21) | <.001 |
| Hb <12 g/dL | 3 | 73 (26) | 129 (40) | <.001 |
| Platelets <150 × 10 ⁹ /L | 5 | 97 (34) | 90 (28) | .094 |
| LDH > UNL | 30 | 61 (23) | 96 (31) | .049 |
| B2M > UNL | 17 | 96 (41) | 156 (60) | <.001 |
| LN size >6 cm | 61 | 8 (3) | 34 (11) | <.001 |
| Albumin <3.5 g/dL | 74 | 15 (8) | 51 (22) | <.001 |
| HBV serology, + | 12 | 23 (8) | 25 (9) | .88 |
| HCV serology, + | 27 | 35 (12) | 67 (21) | .012 |
| Treatment | | | | |
| Watch and wait | 7 | 286 (100) | — | |
| Alk-Mono | — | — | 16 (5) | |
| R-Mono | — | — | 30 (9) | |
| R-Alkylating | — | — | 83 (26) | |
| R-CHOP | — | — | 48 (15) | |
| R-Bendamustine | — | — | 112 (35) | |
| R-Fludarabine | — | — | 3 (1) | |
| Other | — | — | 21 (6) | |

—, not applicable; Alk-Mono, monotherapy with alkylating agents; B2M, β_2 -microglobulin; CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone; Diss-MZL, disseminated MZL; ECOG PS, Eastern Cooperative Oncology Group performance status; Hb, hemoglobin; HBV, hepatitis B virus; HCV, hepatitis C virus; LDH, lactate dehydrogenase; LN, lymph node; R, rituximab.

*Eligible patients were classified as SMZL, ENMZL, and NMZL according to local pathologic diagnosis. Patients with histologic features consistent with MZL with concomitant involvement of the marrow and/or spleen and/or lymph nodes and/or extranodal sites but lacking the diagnostic features of SMZL, NMZL, or ENMZL were categorized as Diss-MZL.

Study design

Consecutive adult patients with a newly diagnosed, histologically confirmed diagnosis of INFL were eligible for the NF10 study without any exclusion criteria, including SMZL, ENMZL, NMZL, lymphoplasmacytic lymphoma, small lymphocytic lymphoma, and CD5⁻ low-grade B-cell lymphoma. Histologic diagnosis was required on tissue or on bone marrow biopsy and was based on local assessment. Patients were managed based on local institutional guidelines; treatment was left to physician discretion and was analyzed according to an intent-to-treat principle. Watch and wait was defined as the decision not to treat patients and by the absence of treatment within the first 3 months from the date of diagnosis. The definition of systemic therapy was applied to the use of systemic chemotherapy and of anti-CD20 monoclonal antibody alone or in combination with 1 or more chemotherapy agents; the use of antibiotics, radiotherapy,

or splenectomy were not considered as systemic therapies. The main aim of the current study was to validate the prognostic role of time to progression on the subgroup of patients with MZL who received immediate systemic therapy.

The main end point of this study was OS; secondary end points were PFS and cause-specific survival.¹⁰ POD24 was defined as experiencing lymphoma progression within 24 months from diagnosis. Survival analysis according to POD24 was only calculated for patients with events within 24 months (early progressors) or for those with at least 24 months of follow-up in case no POD24-defining event was reported (not early progressor). The OS was calculated from the risk-defining event for early progressors; for patients without early progression, OS was computed starting at 24 months from diagnosis, to reduce the effect of early progressive disease patients. Patients censored




Figure 1. OS by POD24 and by MZL subtypes. OS from a risk-defining event after diagnosis in patients with MZL who were immediately treated after diagnosis. (A) Patients with MZL: POD24 rate, 18%; 3-year OS POD24, achieve 95% vs fail 53% ($P < .001$) (HR, 19.5; 95% CI, 8.40-45.4). (B) Patients with SMZL: POD rate, 25%; 3-year OS POD24, achieve 95% vs fail 44% ($P < .001$). (C) Patients with disseminated MZL (Diss-MZL): POD rate, 20%; 3-year OS POD24, achieve 93% vs fail 33% ($P < .001$). (D) Patients with ENMZL: POD rate, 16%; 3-year OS POD24, achieve 98% vs fail 71% ($P < .001$). Association of POD24 with OS could not be assessed for NMZL patients because too few events have been reported in this subgroup to do any inference.

or those who died before 24 months were excluded from analysis. The study was approved by local ethic committees at any active center and signed consent forms were mandatory for all enrolled patients.

Results and discussion

Between July 2010 and July 2018, 1325 INFL cases were registered in the NF10 study by 65 centers in Europe and South America (supplemental Appendix, available on the *Blood* Web site). Demographic and clinical characteristics are summarized in Table 1. Overall, 321 patients who received immediate systemic therapy and who had an adequate follow-up were identified as the main study population. The median follow-up was 43 months (range, 1-92 months). Five-year PFS was 64% (95% confidence interval [CI], 56% to 71%). Salvage treatment of patients with progressive disease was immunochemotherapy in 46 cases (55%), radiotherapy in 6 (7%), and observation in 7 (8%). High-dose therapy followed by autologous stem cell transplant (ASCT) was reported in 3 cases; in 23 cases, it was not possible to obtain details on salvage therapy (27%). Overall, 31 patients died; progressive disease was reported as the cause of death in 19 of 31 cases (61%). Five-year OS was 88% (95% CI, 83% to 92%).

POD24 was reported in 59 of 321 patients (18%). Three-year OS for patients with POD24 was 53% (95% CI, 37% to 67%) with a hazard ratio (HR) of 19.5 (95% CI, 8.4-45.4) when compared with patients without POD24 (88%; 95% CI, 89% to 98%) (Figure 1). Association of POD24 with OS was also confirmed with a lower HR, for patients who were not immediately treated (POD24 rate, 25%; HR for OS, 2.69; 95% CI, 1.04-6.92). The association of POD24 with OS was confirmed in ENMZL, SMZL, and disseminated MZL (Diss-MZL) subgroups (Figure 1). Our data confirm the strong association of time to progression with OS as seen for FL and, more recently, in a study of INFL by the University of Iowa/Mayo Clinic.⁹ Differently from the US series, our study was focused on a homogeneous population of MZL patients prospectively recruited in an international study who

were treated with systemic chemotherapy and/or immunotherapy. Notwithstanding small differences between the 2 studies and the use of 2 slightly different end points, both support the strong association of time to progression with the risk of death.

Recent data on FL suggest that early events could be enriched with transformed cases with more aggressive behavior.¹¹ In our study, 66% of deaths for POD24 patients were referred to lymphoma progression and higher mortality of early relapsed was also confirmed by cause-specific survival analysis; moreover, among the 90 patients who experienced progressive disease, we were able to identify 7 patients with histologically transformed MZL, all of whom were counted as POD24 cases. Thus, if the rate of transformation in our series was low compared with other reported series,^{12,13} our report suggests that histological transformation might play a role in defining the quality of early events.

Another issue with POD24 patients is salvage treatment. In FLs, 2 recent reports suggested that the use of ASCT might be a better option compared with conventional salvage therapies for early relapsers.^{14,15} In MZL, the efficacy of ASCT is controversial and its role as salvage therapy for POD24 patients remains an open research question. Indeed, very few POD24 patients were treated with ASCT in our study.

The finding of early progression (POD24) as a strong marker of poor outcome is useful but its clinical utility to support initial treatment choice is limited. Logistic univariate analysis adjusted by treatment modality (immunochemotherapy vs chemotherapy without rituximab) identified clinical and laboratory parameters associated with higher risk of POD24 (age >60 years, performance status, systemic symptoms, bone marrow involvement, low serum albumin, elevated lactate dehydrogenase, $\beta 2$ microglobulin, low hemoglobin, reduced platelet count, low absolute lymphocyte count). Among tested prognostic scores, the Follicular Lymphoma International Prognostic Index (FLIPI) predicted the risk of POD24 (12% and 27% for 0-2 and 3-5 risk

factors; $P = .001$). Future research efforts should focus on the identification of these high-risk patients at the time of diagnosis in order to enable personalized therapy.

In conclusion, assessment of POD24 predicts subsequent outcome in MZL in need of therapy and its association with OS is confirmed for the main MZL subtypes. Our data have important implications for the management of patients with MZL and for a better understanding of the disease.

Acknowledgment

The authors thank Jacqueline Costa for support in manuscript preparation and language revision.

Authorship

Contribution: S.L. and L.A. designed research and analyzed and interpreted data; L.M. performed statistical analysis and analyzed and interpreted data; and all authors performed research, collected data, and wrote and approved the manuscript.

Conflict-of-interest disclosure: S.L. holds a consultancy/advisory role with Roche, Celgene, Sandoz, Gilead, and Teva. F.C. holds an advisory role with Takeda and Janssen Cilag. M.V. holds an advisory role with Janssen Cilag and Roche and received travel expenses from Janssen Cilag, AbbVie, and Gilead. F.M. holds an advisory role with Roche, Celgene, and Sandoz; received honoraria from Roche, Gilead, Mundipharma, Janssen, and Takeda; received travel expenses from Takeda and Celgene; and received research funding from Roche. D.M. holds an advisory role with Janssen Cilag and AbbVie. O.A. holds an advisory role with Celgene, Takeda, Janssen Cilag, Roche, Servier, and Amgen and has received sponsorships from Gilead, Janssen Cilag, Servier, Celgene, Takeda, and Amgen. L.A. reports consulting or advisory roles for

Bayer, Celgene, Gilead Sciences, Roche, Sandoz, Janssen-Cilag, and Verastem; has received research funding from Gilead Sciences; and reports participation in a speakers' bureau for Celgene. The remaining authors declare no competing financial interests.

A complete list of contributors to the NF10 study appears in the supplemental Appendix.

ORCID profiles: S.L., 0000-0001-8446-2285; M.M., 0000-0002-0905-5927; C.V., 0000-0003-2863-0883; S.F., 0000-0002-9711-1502; O.A., 0000-0002-3095-5313; L.A., 0000-0002-9504-991X.

Correspondence: Stefano Luminari, Programma di Ricerca Clinica Oncematologica, Ematologia, Azienda Unità Sanitaria Locale, IRCCS, Reggio Emilia, Università di Modena e Reggio Emilia, Viale Risorgimento 80, 42123 Reggio Emilia, Italy; e-mail: stefano.luminari@unimore.it; or Luca Arcaini, Divisione di Ematologia, Fondazione IRCCS Policlinico San Matteo, Viale Golgi 19, 27100 Pavia, Italy; e-mail: luca.arcaini@unipv.it.

Footnotes

Submitted 25 February 2019; accepted 25 June 2019. Prepublished online as *Blood* First Edition paper, 10 July 2019; DOI 10.1182/blood.2019001088.

Presented in abstract form at the 60th annual meeting of the American Society of Hematology, San Diego, CA, 7 December 2018.

The online version of this article contains a data supplement.

There is a *Blood* Commentary on this article in this issue.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 USC section 1734.

REFERENCES

1. Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. *Blood*. 2016;127(20):2375-2390.
2. Thieblemont C, Cascione L, Conconi A, et al. A MALT lymphoma prognostic index. *Blood*. 2017;130(12):1409-1417.
3. Arcaini L, Rattotti S, Gotti M, Luminari S. Prognostic assessment in patients with indolent B-cell lymphomas. *ScientificWorldJournal*. 2012;2012:107892.
4. Montalbán C, Abaira V, Arcaini L, et al; Splenic Marginal Zone Lymphoma Study Group. Risk stratification for splenic marginal zone lymphoma based on haemoglobin concentration, platelet count, high lactate dehydrogenase level and extrahilar lymphadenopathy: development and validation on 593 cases [published correction appears in *Br J Haematol*. 2013;162(6):864]. *Br J Haematol*. 2012;159(2):164-171.
5. Casulo C, Byrtek M, Dawson KL, et al. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the national LymphoCare study. *J Clin Oncol*. 2015;33(23):2516-2522.
6. Maurer MJ, Ellin F, Srour L, et al. International assessment of event-free survival at 24 months and subsequent survival in peripheral T-cell lymphoma. *J Clin Oncol*. 2017;35(36):4019-4026.
7. Maurer MJ, Ghesquières H, Jais JP, et al. Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy. *J Clin Oncol*. 2014;32(10):1066-1073.
8. Visco C, Tisi MC, Evangelista A, et al; Fondazione Italiana Linfomi and the Mantle Cell Lymphoma Network. Time to progression of mantle cell lymphoma after high-dose cytarabine-based regimens defines patients risk for death. *Br J Haematol*. 2019;185(5):940-944.
9. Tracy SI, Larson MC, Feldman AL, et al. The utility of prognostic indices, early events, and histological subtypes on predicting outcomes in non-follicular indolent B-cell lymphomas. *Am J Hematol*. 2019;94(6):658-666.
10. Cheson BD, Fisher RI, Barrington SF, et al; United Kingdom National Cancer Research Institute. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. *J Clin Oncol*. 2014;32(27):3059-3068.
11. Freeman CL, Savage KJ, Villa D, et al. Frontline therapy with bendamustine and rituximab (BR) in follicular lymphoma: prognosis among patients with progression of disease by 24 months (POD24) is poor with majority having transformed lymphoma [abstract]. *Blood*. 2018;132(suppl 1):Abstract 2873.
12. Conconi A, Franceschetti S, Aprile von Hohenstaufen K, et al. Histologic transformation in marginal zone lymphomas. *Ann Oncol*. 2015;26(11):2329-2335.
13. Alderuccio JP, Zhao W, Desai A, et al. Risk factors for transformation to higher-grade lymphoma and its impact on survival in a large cohort of patients with marginal zone lymphoma from a single institution [published online ahead of print 12 October 2018]. *J Clin Oncol*. doi:10.1200/JCO.18.00138.
14. Casulo C, Friedberg JW, Ahn KW, et al. Autologous transplantation in follicular lymphoma with early therapy failure: a national LymphoCare study and Center for International Blood and Marrow Transplant research analysis. *Biol Blood Marrow Transplant*. 2018;24(6):1163-1171.
15. Jurinovic V, Metzner B, Pfreundschuh M, et al. Autologous stem cell transplantation for patients with early progression of follicular lymphoma: a follow-up study of 2 randomized trials from the German Low Grade Lymphoma Study Group. *Biol Blood Marrow Transplant*. 2018;24(6):1172-1179.